Consensus $2.95. Cuts FY24 revenue view to up 1%-2% from up 3%. The company said, “Given the unprecedented impact of Hurricane Helene on the company’s North Cove operations and related production, Baxter (BAX) is adjusting its full-year 2024 financial outlook to reflect the estimated impact of the hurricane on its fourth-quarter results. As a result of the hurricane, Baxter expects total company fourth-quarter sales to be negatively impacted by approximately $200 million, including an estimated $40 to $50 million impact on Kidney Care sales and approximately $150 to $160 million impact on Medical Products & Therapies sales. Total company adjusted diluted EPS (including discontinued operations) are expected to be negatively impacted by $0.15 to $0.20 per share.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX:
- Baxter reports Q3 adjusted EPS 80c, consensus 78c
- Options Volatility and Implied Earnings Moves Today, November 08, 2024
- Unusually active option classes on open November 7th
- Baxter International Sells Kidney Care to Carlyle Group
- Baxter International Inc (BAX) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
